Quantifying home medication regimen changes and quality of life in patients receiving nocturnal home hemodialysis

Hemodialysis International

Volumn 15, Issue 2, 2011, Pages 234-242

  Cardone, Katie E ^a,b   Manley, Harold J ^c   Grabe, Darren W ^a,b   Meola, Shari ^d   Hoy, Christopher D ^d   Bailie, George R ^a,b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b Albany Nephrology Pharmacy ANephRx Group   (United States)

^c Village Health Disease Management   (United States)

^d Hortense and Louis Rubin Dialysis Center   (United States)

Author keywords

Adherence; Medication regimen; Nocturnal home hemodialysis; Pill burden; Quality of life

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; ANTIVIRUS AGENT; ASCORBIC ACID; CARDIAC GLYCOSIDE; CLOPIDOGREL; DIURETIC AGENT; DOXERCALCIFEROL; ERYTHROPOIETIN; FERROUS SULFATE; GLUCONIC ACID; HERBACEOUS AGENT; INSULIN LISPRO; IRON DERIVATIVE; LEVOTHYROXINE; MINERALOCORTICOID; NITRIC ACID DERIVATIVE; PANTOPRAZOLE; RANITIDINE; SERTRALINE; SEVELAMER; UNINDEXED DRUG; VITAMIN; VITAMIN B GROUP;

ADULT; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; HOME CARE; HOME DIALYSIS; HUMAN; MALE; NOCTURNAL HOME HEMODIALYSIS; PATIENT COMPLIANCE; PILOT STUDY; QUALITY OF LIFE; RETROSPECTIVE STUDY; SHORT FORM 36;

DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMODIALYSIS, HOME; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 79954627095     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2011.00539.x     Document Type: Article

References (31)

1. United States Renal Data System. USRDS 2010 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, The National Institute of Diabetes and Digestive and Kidney Diseases, 2010.
2. Kestenbaum B, Belozeroff V. Mineral metabolism disturbances in patients with chronic kidney disease. Eur J Clin Invest. 2007; 37:607-622.
3. McFarlane SI, Chen SC, Whaley-Connell AT, et al. Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2008; 51 (Suppl 2):S46-S55.
4. McCullough PA, Li S, Jurkovitz CL, et al. CKD and cardiovascular disease in screened high-risk volunteer and general populations: The Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2008; 51 (Suppl 2):S38-S45.
5. Vanderpoel DR, Hussein MA, Watson-Heidari T, Perry A. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: A retrospective database analysis. Clin Ther. 2004; 26:2066-2075.
6. Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009; 4:1089-1096.
7. Bourgeois FT, Shannon MW, Valim C, Mandl KD. Adverse drug events in the outpatient setting: An 11-year national analysis. Pharmacoepidemiol Drug Saf. 2010; 19:901-10.
8. Pierratos A. Nocturnal home haemodialysis: An update on a 5 year experience. Nephrol Dial Transplant. 1999; 14:2835-2840.
9. Walsh M, Culleton B, Tonelli M, Manns B. A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of life. Kidney Int. 2005; 67:1500-1508.
10. Nesrallah G, Suri R, Moist L, Kortas C, Lindsay RM. Volume control and blood pressure management in patients undergoing quotidian hemodialysis. Am J Kidney Dis. 2003; 42 (Suppl):S13-S17.
11. Chan CT, Harvey PJ, Picton P, Pierratos A, Miller JA, Floras JS. Short-term blood pressure, noradrenergic, and vascular effects of nocturnal home hemodialysis. Hypertension. 2003; 42:925-931.
12. Chan CT, Jain V, Picton P, Pierratos A, Floras JS. Nocturnal hemodialysis increases arterial baroreflex sensitivity and compliance and normalizes blood pressure of hypertensive patients with end-stage renal disease. Kidney Int. 2005; 68:338-344.
13. Mucsi I, Hercz G, Uldall R, Ouwendyk M, Francoeur R, Pierratos A. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int. 1998; 53:1399-1404.
14. Lindsay RM, Alhejaili F, Nesrallah G, et al. Calcium and phosphate balance with quotidian hemodialysis. Am J Kidney Dis. 2003; 42 (Suppl):S24-S29.
15. Toussaint N, Boddington J, Simmonds R, Waldron C, Somerville C, Agar J. Calcium phosphate metabolism and bone mineral density with nocturnal hemodialysis. Hemodial Int. 2006; 10:280-286.
16. Yuen D, Richardson RMA, Fenton SSA, McGrath-Chong ME, Chan CT. Quotidian nocturnal hemodialysis improves cytokine profile and enhances erythropoietin responsiveness. Am Soc Artif Intern Organ J. 2005; 51:236-241.
17. Schwartz DI, Pierratos A, Richardson RMA, Fenton SSA, Chan CT. Impact of nocturnal home hemodialysis on anemia management in patients with end-stage renal disease. Clin Nephrol. 2005; 63:202-208.
18. Rao M, Muirhead N, Klarenbach S, Moist L, Lindsay RM. Management of anemia with quotidian hemodialysis. Am J Kidney Dis. 2003; 42 (Suppl):S18-S23.
19. McFarlane PA, Bayoumi AM, Pierratos A, Redelmeier DA. The quality of life and cost utility of home nocturnal and conventional in-center hemodialysis. Kidney Int. 2003; 64:1004-1011.
20. Heidenheim AP, Muirhead N, Moist L, Lindsay RM. Patient quality of life on quotidian hemodialysis. Am J Kidney Dis. 2003; 42 (Suppl):S36-S41.
21. George J, Phun YT, Bailey MJ, Kong DCM, Stewart K. Development and validation of the Medication Regimen Complexity Index. Ann Pharmacother. 2004; 38:1369-1376.
22. Chan C, Floras JS, Miller JA, Pierratos A. Improvement in ejection fraction by nocturnal haemodialysis in end-stage renal failure patients with coexisting heart failure. Nephrol Dial Transplant. 2002; 17:1518-1521.
23. Bugeja AL, Chan CT. Improvement in lipid profile by nocturnal hemodialysis in patients with end stage renal-disease. ASAIO J. 2004; 50:328-331.
24. Manley HJ, Garvin CG, Drayer DK, et al. Medication prescribing patterns in ambulatory hemodialysis patients: Comparisons of USRDS to a large not-for-profit dialysis provider. Nephrol Dial Transplant. 2004; 19:1842-1848.
25. Loghman-Adham M. Medication noncompliance in patients with chronic disease: Issues in dialysis and renal transplantation. Am J Manag Care. 2003; 9:155-171.
26. Culleton BF, Walsh M, Klarenbach SW, et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: A randomized controlled trial. J Am Med Assoc. 2007; 298:1291-1299.
27. Manns BJ, Walsh MW, Culleton BF, et al. Alberta Kidney Disease Network. Nocturnal hemodialysis does not improve overall measure of quality of life compared to conventional hemodialysis. Kidney Int. 2009; 75:542-554.
28. Kutner NG, Zhang R, McClellan WM, Cole SA. Psychosocial predictors of non-compliance in haemodialysis and peritoneal dialysis patients. Nephrol Dial Transplant. 2002; 17:93-99.
29. Holley JL, DeVore CC. Why all prescribed medications are not taken: Results from a survey of chronic dialysis patients. Adv Perit Dial. 2006; 22:162-166.
30. Kutner NG. Improving compliance in dialysis patients: Does anything work? Semin Dial. 2001; 14:324-327.
31. Pipkin M, Eggers PW, Larive B, et al. Recruitment and training for home hemodialysis: Experience and lessons from the Nocturnal Dialysis Trial. Clin J Am Soc Nephrol. 2010; 5:1614-1620.